Your session is about to expire
← Back to Search
Keratinocyte growth factor for Alopecia
Study Summary
This trial is testing a new topical formula to see if it can prevent hair loss from chemotherapy.
- Alopecia
- Chemotherapy-Induced Change
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the fundamental aims of this trial?
"This clinical trial will last for approximately four months, and its primary purpose is to gauge the effectiveness of KGF-HS as a topical formula against hair loss caused by chemotherapy. Other objectives include assessing hair preservation with the Alopecial Pictoral Tool (CTCAE v4.0 grades 0-2), evaluating regrowth speed in comparison to control groups, and gauging quality of life through HADS scores ranging from 0 to 21 (normal: 0-7; borderline case: 8-10; abnormal: 11-21)."
Are any openings remaining for participants in this medical trial?
"Reputable sources at clinicaltrials.gov demonstrate that this medical investigation is presently not recruiting participants, having been initially posted on April 27th 2020 and last revised on June 15th 2022. Fortunately, there are 86 alternative trials actively enrolling patients currently."
Share this study with friends
Copy Link
Messenger